Prediction of riboswitch as a potential drug target and design of its optimal inhibitors for Mycobacterium tuberculosis

Non-homologous proteins have been widely identified as major drug targets in host-parasite diseases like tuberculosis. The available antibiotic treatment for infectious diseases have suffered a major setback due to the development of drug resistance by the pathogen. Therefore, in the present study the riboswitch is explored as a promising alternative potential drug target. A framework has been developed for the prediction of riboswitch as a potential drug target and design of corresponding inhibitor for M. tuberculosis bacteria by molecular docking simulation based virtual screening. The virtual screening is performed by using molecular library containing 5017 diverse ligands against tuberculosis bacterial riboswitch. Thus, it is concluded that the riboswitches can be alternative potential drug-target for infectious disease to overcome the present issues of existing antibiotic drugs like their side effects and drug resistance, etc. Further a single riboswitch can be a drug target for multiple strains of bacteria and other pathogenic organisms.

[1]  Ferenc Zsila,et al.  Molecular modeling of the non-covalent binding of the dietary tomato carotenoids lycopene and lycophyll, and selected oxidative metabolites with 5-lipoxygenase. , 2006, Bioorganic & medicinal chemistry.

[2]  B. Iorga,et al.  Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the “blind docking” approach , 2006, Journal of molecular modeling.

[3]  Sean R. Eddy,et al.  Rfam: an RNA family database , 2003, Nucleic Acids Res..

[4]  J. Ungwitayatorn,et al.  Molecular docking study on anticancer activity of plant-derived natural products , 2010, Medicinal Chemistry Research.

[5]  Hsien-Da Huang,et al.  Computational identification of riboswitches based on RNA conserved functional sequences and conformations. , 2009, RNA.

[6]  D. Crothers,et al.  The speed of RNA transcription and metabolite binding kinetics operate an FMN riboswitch. , 2005, Molecular cell.

[7]  Ian R Kleckner,et al.  Tuning riboswitch regulation through conformational selection. , 2011, Journal of molecular biology.

[8]  Thomas Dandekar,et al.  Riboswitch finder tool for identification of riboswitch RNAs , 2004, Nucleic Acids Res..

[9]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[10]  E. Hazai,et al.  Molecular modeling of non-covalent binding of homochiral (3S,3'S)-astaxanthin to matrix metalloproteinase-13 (MMP-13). , 2006, Bioorganic & medicinal chemistry.

[11]  Donald Hamelberg,et al.  Atomistic basis for the on–off signaling mechanism in SAM-II riboswitch , 2009, Nucleic acids research.

[12]  Feng Ding,et al.  RNA-Puzzles: a CASP-like evaluation of RNA three-dimensional structure prediction. , 2012, RNA.

[13]  Daniel N. Wilson,et al.  Probing translation with small-molecule inhibitors. , 2010, Chemistry & biology.

[14]  M. Gelfand,et al.  Riboswitches: the oldest mechanism for the regulation of gene expression? , 2004, Trends in genetics : TIG.

[15]  Namhee Kim,et al.  Analysis of riboswitch structure and function by an energy landscape framework. , 2009, Journal of molecular biology.

[16]  H. Baird.  CHARACTERIZATION OF MYCOSIN FAMILY PROTEASES, NOVEL DRUG TARGETS OF MYCOBACTERIUM TUBERCULOSIS , 2007 .

[17]  D. van der Spoel,et al.  Efficient docking of peptides to proteins without prior knowledge of the binding site , 2002, Protein science : a publication of the Protein Society.

[18]  Enrique Merino,et al.  RibEx: a web server for locating riboswitches and other conserved bacterial regulatory elements , 2005, Nucleic Acids Res..

[19]  J. Naismith,et al.  Novel Inhibitors of an Emerging Target in Mycobacterium tuberculosis; Substituted Thiazolidinones as Inhibitors of dTDP‐Rhamnose Synthesis. , 2003 .

[20]  S. K. Desai,et al.  Synthetic Riboswitches That Induce Gene Expression in Diverse Bacterial Species , 2010, Applied and Environmental Microbiology.

[21]  Shana Topp,et al.  Emerging applications of riboswitches in chemical biology. , 2010, ACS chemical biology.

[22]  N. Kulshina,et al.  Riboswitch function: Flipping the switch or tuning the dimmer? , 2010, RNA biology.

[23]  T. Schlick,et al.  Computational approaches to RNA structure prediction, analysis, and design. , 2011, Current opinion in structural biology.

[24]  Amiram Goldblum,et al.  High quality binding modes in docking ligands to proteins , 2008, Proteins.

[25]  Somdutt Mujwar,et al.  Prediction of Riboswitch as a Potential Drug Target for Infectious Diseases: An Insilico Case Study of Anthrax , 2015 .

[26]  Pradipta Bandyopadhyay,et al.  Riboswitch Detection Using Profile Hidden Markov Models , 2009, BMC Bioinformatics.

[27]  D. Kirschner,et al.  The human immune response to Mycobacterium tuberculosis in lung and lymph node. , 2004, Journal of theoretical biology.

[28]  K. Mdluli,et al.  Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. , 2007, Infectious disorders drug targets.

[29]  Feng Ding,et al.  iFoldRNA: three-dimensional RNA structure prediction and folding , 2008, Bioinform..

[30]  Jorng-Tzong Horng,et al.  RNALogo: a new approach to display structural RNA alignment , 2008, Nucleic Acids Res..

[31]  V. Mizrahi,et al.  A Riboswitch Regulates Expression of the Coenzyme B12-Independent Methionine Synthase in Mycobacterium tuberculosis: Implications for Differential Methionine Synthase Function in Strains H37Rv and CDC1551 , 2007, Journal of bacteriology.

[32]  J. Sellers,et al.  Mechanism of Blebbistatin Inhibition of Myosin II* , 2004, Journal of Biological Chemistry.

[33]  Shahista Nisa,et al.  ParA: A Novel Target for Anti-Tubercular Drug Discovery , 2010 .

[34]  R. Breaker,et al.  Riboswitches as versatile gene control elements. , 2005, Current opinion in structural biology.